AR027358A1 - Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas - Google Patents

Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas

Info

Publication number
AR027358A1
AR027358A1 ARP010100505A ARP010100505A AR027358A1 AR 027358 A1 AR027358 A1 AR 027358A1 AR P010100505 A ARP010100505 A AR P010100505A AR P010100505 A ARP010100505 A AR P010100505A AR 027358 A1 AR027358 A1 AR 027358A1
Authority
AR
Argentina
Prior art keywords
polypeptide
protease
variant
proteins
reduce
Prior art date
Application number
ARP010100505A
Other languages
English (en)
Original Assignee
Genencor Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Int filed Critical Genencor Int
Publication of AR027358A1 publication Critical patent/AR027358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)

Abstract

Para reducir el potencial inmunogénico del uso de la proteasa, figuran mejores procesos de produccion, que reducen el contacto potencial controlando yminimizando las concentraciones de partículas de polvo o aerosol con proteasa en suspension en el ai re de lugar de trabajo; mejores procesos de granulacion,que reducen la proporcion de polvo o aerosol realmente producida a partir del producto proteasa; y mejores procesos de recuperacion para reducir el nivel decontaminantes potencialmente alergénic os en el producto final. Sin embargo, los esfuerzospara reducir la alergenicidad de la proteasa, per se, han tenido unéxito relativo. Alternativamente, se han hecho esfuerzos para enmascarar los epítopos de la proteasa que son reconocidos por la inmu noglobulina E (igE) en losindividuos hipersensibles o para incrementar o modificar la naturaleza de los determinantes antigénicos agregando polímeros o péptidos/proteínas a la proteasaproblemática. Se proponen proteínas que producen las respuestas in munogénicas deseadas, así como métodos de identificacion y produccion de dichas proteínas, ymétodos de uso de dichas proteínas. Una variante de un polipéptido de interés que comprende un epítopo de células T, en donde dicha variante difiere delpolipé ptido de interés mencionado por tener un epítopo de células T alterado de manera tal que dicha variante y dicho polipéptido produzcan diferentesrespuestas inmunogénicas en un individuo. La respuesta inmunogénica mencionada producida por la variante m encionada puede ser menor o mayor que la respuestainmunogénica mencionada producida por el polipéptido de interés mencionado. El polipéptido de interés mencionado puede ser seleccionado entre los integrantesde un grupo compuesto por enzimas, hormonas , factores, vacunas y citoquinas. Un ácido nucleico que codifica la variante del polipéptido de interés y un vectorde expresion que comprende a dicho ácido nucleico. Una célula huésped transformada con dicho vector de expresion. Una composicion para la limpieza, unacomposicion para alimentos de animales, o una composicion para el tratamiento de productos textiles que comprende la variante de polipéptido. Un método para
ARP010100505A 2000-02-08 2001-02-02 Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas AR027358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/500,135 US6838269B1 (en) 1998-04-15 2000-02-08 Proteins producing an altered immunogenic response and methods of making and using the same

Publications (1)

Publication Number Publication Date
AR027358A1 true AR027358A1 (es) 2003-03-26

Family

ID=23988185

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100505A AR027358A1 (es) 2000-02-08 2001-02-02 Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas

Country Status (12)

Country Link
US (1) US6838269B1 (es)
EP (1) EP1254240B1 (es)
JP (1) JP5112587B2 (es)
KR (1) KR20020073582A (es)
CN (3) CN1721442A (es)
AR (1) AR027358A1 (es)
AT (1) ATE355377T1 (es)
AU (1) AU3651201A (es)
CA (1) CA2399019A1 (es)
DE (1) DE60126915T2 (es)
DK (1) DK1254240T3 (es)
WO (1) WO2001059130A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967080B1 (en) * 1990-12-05 2005-11-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
JP2004532618A (ja) * 2001-02-06 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたレプチン
EP1461072A4 (en) * 2001-12-31 2005-02-09 Genencor Int PROTEASES PRODUCING MODIFIED IMMUNOLOGICAL RESPONSE AND METHODS OF PRODUCTION AND USE
EP2287320B1 (en) * 2002-01-16 2014-10-01 Danisco US Inc. Multiply-substituted protease variants
US20050239043A1 (en) * 2002-02-26 2005-10-27 Harding Fiona A Subtilisin carlsberg proteins with reduced immunogenicity
US20060228791A1 (en) * 2002-06-26 2006-10-12 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
EP1597363B1 (en) * 2003-02-26 2015-07-15 Danisco US Inc. Amylases producing an altered immunogenic response and methods of making and using the same
EP2500423B1 (en) * 2003-02-26 2015-06-17 Danisco US Inc. Amylases producing an altered immunogenic response and methods of making and using the same
KR20070116650A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 조성물
US7691579B2 (en) * 2005-04-15 2010-04-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
ES2594893T3 (es) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
EP3164486B1 (en) 2014-07-04 2020-05-13 Novozymes A/S Subtilase variants and polynucleotides encoding same
CN106661566A (zh) 2014-07-04 2017-05-10 诺维信公司 枯草杆菌酶变体以及编码它们的多核苷酸
CN109715792A (zh) * 2016-06-03 2019-05-03 诺维信公司 枯草杆菌酶变体和对其进行编码的多核苷酸

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1142105A (en) 1978-07-04 1983-03-01 Peter Tang Protease product of reduced allergenicity
US5801038A (en) * 1984-05-29 1998-09-01 Genencor International Inc. Modified subtilisins having amino acid alterations
WO1992010755A1 (en) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
US5593877A (en) * 1993-03-11 1997-01-14 The Rockefeller University Nucleic acid and recombinant production of vespid venom hyaluronidase
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0793726A1 (en) 1994-11-24 1997-09-10 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
US5951980A (en) * 1995-01-06 1999-09-14 Leuven Research & Development Vzw Identification, production and use of new staphylokinase derivatives with reduced immunogenicity
JP3715320B2 (ja) 1995-05-05 2005-11-09 ノボザイムス アクティーゼルスカブ プロテアーゼ変異体及び組成物
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
CA2242488A1 (en) 1996-02-15 1997-08-21 Novo Nordisk A/S Conjugation of polypeptides
BR9712878A (pt) 1996-11-04 2000-02-01 Novo Nordisk As Variante de enzima subtilase, processos para a identificação de uma variante de protease apresentando estabilidade autoproteolìtica e paraq a produção de uma enzima subtilase mutante e de uma variante de subtilase, sequência de dna, vetor, célula hospedeira microbiana, composição e uso de uma variante de subtilase.
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
AU8595298A (en) 1997-07-29 1999-02-22 The Administrators Of The Tulane Eductional Fund Prediction, detection, and design of t cell epitopes
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
CA2238660A1 (en) 1998-05-22 1999-11-22 Janet Chantler Gene sequences of rubella virus associated with attenuation
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.

Also Published As

Publication number Publication date
CN1721442A (zh) 2006-01-18
KR20020073582A (ko) 2002-09-27
CN1418253A (zh) 2003-05-14
EP1254240B1 (en) 2007-02-28
CN101906464A (zh) 2010-12-08
WO2001059130A2 (en) 2001-08-16
DK1254240T3 (da) 2007-07-02
AU3651201A (en) 2001-08-20
DE60126915D1 (de) 2007-04-12
EP1254240A2 (en) 2002-11-06
CN101906464B (zh) 2013-03-27
WO2001059130A3 (en) 2002-03-07
CA2399019A1 (en) 2001-08-16
ATE355377T1 (de) 2006-03-15
JP5112587B2 (ja) 2013-01-09
DE60126915T2 (de) 2007-11-15
JP2004500088A (ja) 2004-01-08
US6838269B1 (en) 2005-01-04

Similar Documents

Publication Publication Date Title
AR027358A1 (es) Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas
AR248426A1 (es) Produccion de particulas incorporadas a un virus vegetal que contiene un peptido antigenico, con el fin de preparar una vacuna de virus animal.
AR047345A1 (es) Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes
NO20011586D0 (no) Nye metoder for terapeutisk vaksinasjon
CA2297786A1 (en) New immunoprotective influenza antigen and its use in vaccination
JP2001512748A5 (es)
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
DE69334066D1 (de) Impfstoffzusammensetzungen für mukosale Abgabe
HUP0303753A2 (hu) Fúziós fehérjék immunogenitásának csökkentése
NZ710626A (en) Pcsk9 vaccine
ATE70717T1 (de) Vermehrung der antigenimmunogenizitaet.
NO972642L (no) Fremgangsmåte for fremstilling av en proteinanalog til Bordetella-eksotoksin
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
ATE408696T1 (de) Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff
DE60331224D1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
ES543026A0 (es) Un metodo para preparar una vacuna pra inducir inmunidad a la tosferina.
DK0425082T3 (da) Vacciner
FI955150A0 (fi) OspC-antigeenirokotteiden immunogeenisia formulaatioita lyymisairauden ehkäisyyn ja hoitoon ja rekombinanttimenetelmiä antigeenien valmistamiseksi
JP2023024998A5 (es)
ATE427757T1 (de) Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
Middlebrook Protection strategies against botulinum toxin
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
BR9604989A (pt) Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção
ATE494909T1 (de) Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung
NO20041564L (no) Infeksios lakse anemi-virus vaksine